Cantor Fitzgerald Issues Negative Outlook for RARE Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of Ultragenyx Pharmaceutical in a research report issued on Wednesday, August 6th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will post earnings of ($5.19) per share for the year, down from their previous forecast of ($5.15). Cantor Fitzgerald currently has a “Overweight” rating and a $105.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. Cantor Fitzgerald also issued estimates for Ultragenyx Pharmaceutical’s FY2026 earnings at ($3.21) EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.10. The firm had revenue of $166.50 million during the quarter, compared to analysts’ expectations of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. Ultragenyx Pharmaceutical’s revenue for the quarter was up 13.2% on a year-over-year basis. During the same period in the prior year, the company posted ($1.52) earnings per share.

A number of other brokerages have also commented on RARE. HC Wainwright raised shares of Ultragenyx Pharmaceutical to a “buy” rating and set a $80.00 price objective for the company in a research report on Monday, July 28th. Wells Fargo & Company cut their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating for the company in a research report on Thursday, July 10th. Guggenheim reaffirmed a “buy” rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Wedbush lowered their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating on the stock in a research note on Monday, July 14th. Finally, Morgan Stanley lowered their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, July 14th. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.50.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock opened at $27.54 on Friday. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of -4.98 and a beta of 0.25. Ultragenyx Pharmaceutical has a fifty-two week low of $25.81 and a fifty-two week high of $60.37. The firm has a fifty day moving average price of $33.32 and a two-hundred day moving average price of $36.78.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds and other institutional investors have recently made changes to their positions in RARE. GAMMA Investing LLC grew its position in Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 323 shares in the last quarter. Parallel Advisors LLC grew its position in Ultragenyx Pharmaceutical by 1,061.9% in the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 669 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new position in Ultragenyx Pharmaceutical in the fourth quarter valued at $35,000. ANTIPODES PARTNERS Ltd bought a new position in Ultragenyx Pharmaceutical in the first quarter valued at $57,000. Finally, Headlands Technologies LLC bought a new position in Ultragenyx Pharmaceutical in the first quarter valued at $59,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the stock in a transaction on Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the sale, the director directly owned 15,344 shares in the company, valued at approximately $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 5.50% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.